Difficulty: Medium
Average Score: 64%
Practice
A 61-year-old man with osteoarthritis comes to the clinic for follow-up. His arthritis has been worsening over the past year. He has pain constantly throughout the day. He reports the only medication that was effective for him was celecoxib, which was pulled from the market. He is willing to try anything that will improve his pain at this point. What side effect is the reason for the removal of celecoxib from the market?
Correct answer
D
Rationale
The correct answer is D) Increased risk of thrombosis. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that was withdrawn from the market due to its association with an increased risk of cardiovascular events, particularly thrombosis (formation of blood clots). This decision was based on various clinical studies and regulatory assessments that demonstrated the heightened cardiovascular risks associated with the use of celecoxib.
Option A) Increased risk of cardiomyopathy is incorrect because the primary concern with celecoxib was related to cardiovascular events such as thrombosis, not cardiomyopathy.
Option B) Increased risk of bleeding is incorrect as bleeding is not a common side effect associated with celecoxib use. The main issue was the cardiovascular risks.
Option C) Increased risk of pulmonary fibrosis is incorrect because pulmonary fibrosis is not a known side effect of celecoxib. The focus was on cardiovascular risks, particularly thrombosis.
In an educational context, it is crucial for healthcare providers to stay updated on the safety profiles of medications to make informed decisions when prescribing drugs to patients. Understanding the reasons behind the withdrawal of drugs like celecoxib helps healthcare professionals assess the risks and benefits of alternative treatment options for patients with conditions like osteoarthritis. It also highlights the importance of monitoring and managing potential adverse effects of medications to ensure patient safety and optimal outcomes.
Option A) Increased risk of cardiomyopathy is incorrect because the primary concern with celecoxib was related to cardiovascular events such as thrombosis, not cardiomyopathy.
Option B) Increased risk of bleeding is incorrect as bleeding is not a common side effect associated with celecoxib use. The main issue was the cardiovascular risks.
Option C) Increased risk of pulmonary fibrosis is incorrect because pulmonary fibrosis is not a known side effect of celecoxib. The focus was on cardiovascular risks, particularly thrombosis.
In an educational context, it is crucial for healthcare providers to stay updated on the safety profiles of medications to make informed decisions when prescribing drugs to patients. Understanding the reasons behind the withdrawal of drugs like celecoxib helps healthcare professionals assess the risks and benefits of alternative treatment options for patients with conditions like osteoarthritis. It also highlights the importance of monitoring and managing potential adverse effects of medications to ensure patient safety and optimal outcomes.